Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · IEX Real-Time Price · USD
65.72
-3.99 (-5.72%)
At close: Apr 18, 2024, 4:00 PM
66.50
+0.78 (1.19%)
After-hours: Apr 18, 2024, 7:59 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 119.92, with a low estimate of 81 and a high estimate of 190. The average target predicts an increase of 82.47% from the current stock price of 65.72.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 3 | 2 | 3 | 3 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 9 | 10 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +62.81% | Apr 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $190 | Strong Buy | Maintains | $190 | +189.11% | Apr 2, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $108 → $109 | Strong Buy | Maintains | $108 → $109 | +65.86% | Mar 28, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $150 | Strong Buy | Maintains | $150 | +128.24% | Mar 26, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $123 → $128 | Buy | Maintains | $123 → $128 | +94.77% | Mar 26, 2024 |
Financial Forecast
Revenue This Year
387.31M
from 270.60M
Increased by 43.13%
Revenue Next Year
706.35M
from 387.31M
Increased by 82.37%
EPS This Year
-3.88
from -5.27
EPS Next Year
1.00
from -3.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 472.6M | 989.7M | 1.6B | 2.3B | 2.8B |
| Avg | 387.3M | 706.4M | 1.1B | 1.6B | 2.1B |
| Low | 332.8M | 528.2M | 841.1M | 1.0B | 1.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 74.6% | 155.5% | 125.5% | 104.4% | 72.9% |
| Avg | 43.1% | 82.4% | 60.1% | 43.4% | 29.5% |
| Low | 23.0% | 36.4% | 19.1% | -8.6% | -10.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.95 | 5.15 | 15.27 | 10.63 | 12.31 |
| Avg | -3.88 | 1.00 | 7.69 | 8.07 | 11.95 |
| Low | -4.92 | -2.46 | -0.33 | 5.60 | 11.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,429.7% | 38.2% | 52.4% |
| Avg | - | - | 670.1% | 5.0% | 48.1% |
| Low | - | - | - | -27.2% | 42.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.